ABSTRACT
As stated by Korpás and Tomori (1979), cough is the most important airway protective reflex which provides airway defensive responses to nociceptive stimuli. They recognized that active expiratory efforts, due to the activation of caudal ventral respiratory group (cVRG) expiratory premotoneurons, are the prominent component of coughs. Here, we discuss data suggesting that neurons located in the cVRG have an essential role in the generation of both the inspiratory and expiratory components of the cough reflex. Some lines of evidence indicate that cVRG expiratory neurons, when strongly activated, may subserve the alternation of inspiratory and expiratory cough bursts, possibly owing to the presence of axon collaterals. Of note, experimental findings such as blockade or impairment of glutamatergic transmission to the cVRG neurons lead to the view that neurons located in the cVRG are crucial for the production of the complete cough motor pattern. The involvement of bulbospinal expiratory neurons seems unlikely since their activation affects differentially expiratory and inspiratory muscles, while their blockade does not affect baseline inspiratory activity. Thus, other types of cVRG neurons with their medullary projections should have a role and possibly contribute to the fine tuning of the intensity of inspiratory and expiratory efforts.
Subject(s)
Cough/physiopathology , Exhalation/physiology , Inhalation/physiology , Medulla Oblongata/physiology , Reflex/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Cough/prevention & control , Excitatory Amino Acid Antagonists/administration & dosage , Exhalation/drug effects , Humans , Inhalation/drug effects , Medulla Oblongata/drug effects , Microinjections/methods , Neurons/drug effects , Neurons/physiology , Phrenic Nerve/drug effects , Phrenic Nerve/physiology , Reflex/drug effects , Respiratory Mechanics/drug effects , Respiratory Mechanics/physiologyABSTRACT
Nucleus accumbens dopamine plays a key role in reward-directed approach. Past findings suggest that dopamine's role in the expression of learned behavior diminishes with extended training. However, little is known about the central substrates that mediate the shift to dopamine-independent reward approach. In the present study, rats approached and inserted the head into a reward compartment in response to a cue signaling food delivery. On days 4 and 5 of 28-trial-per-day sessions, D1 receptor antagonist R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) infused to the NAc core reduced the probability and speed of cued approach. The disruptive effect of D1 receptor blockade was specific to the nucleus accumbens core and not seen with drug infusions to nearby dopamine target regions. In rats that received drug infusions after extended training (days 10 or 11), accumbens core D1 receptor blockade produced little effect on the expression of the same behavior. These results could have been due to a continued accumbens mediation of cued approach even after the behavior had become independent of accumbens D1 receptors. However, accumbens core ionotropic glutamate receptor blockade disrupted cued approach during early but not late stages of training, similar to the effects of D1 antagonist infusions. The results suggest that with extended training, a nucleus accumbens D1-dependent behavior becomes less dependent not only on nucleus accumbens D1 transmission but also on excitatory transmission in the nucleus accumbens. These findings fill an important gap in a growing literature on reorganization of striatal function over the course of training.
Subject(s)
Choice Behavior/physiology , Dopamine/physiology , Learning/physiology , Nucleus Accumbens/physiology , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , 2-Amino-5-phosphonovalerate/administration & dosage , 2-Amino-5-phosphonovalerate/pharmacology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Benzazepines/administration & dosage , Benzazepines/pharmacology , Choice Behavior/drug effects , Dopamine/metabolism , Learning/drug effects , Male , Microinjections , Nucleus Accumbens/drug effects , Quinpirole/pharmacology , Rats , Reward , Time FactorsABSTRACT
Chronic pain is a serious debilitating disease for which effective treatment is still lacking. Acid-sensing ion channel 1a (ASIC1a) has been implicated in nociceptive processing at both peripheral and spinal neurons. However, whether ASIC1a also contributes to pain perception at the supraspinal level remains elusive. Here, we report that ASIC1a in ACC is required for thermal and mechanical hypersensitivity associated with chronic pain. ACC-specific genetic deletion or pharmacological blockade of ASIC1a reduced the probability of cortical LTP induction and attenuated inflammatory thermal hyperalgesia and mechanical allodynia in male mice. Using cell type-specific manipulations, we demonstrate that ASIC1a in excitatory neurons of ACC is a major player in cortical LTP and pain behavior. Mechanistically, we show that ASIC1a tuned pain-related cortical plasticity through protein kinase C λ-mediated increase of membrane trafficking of AMPAR subunit GluA1 in ACC. Importantly, postapplication of ASIC1a inhibitors in ACC reversed previously established nociceptive hypersensitivity in both chronic inflammatory pain and neuropathic pain models. These results suggest that ASIC1a critically contributes to a higher level of pain processing through synaptic potentiation in ACC, which may serve as a promising analgesic target for treatment of chronic pain.SIGNIFICANCE STATEMENT Chronic pain is a debilitating disease that still lacks effective therapy. Ion channels are good candidates for developing new analgesics. Here, we provide several lines of evidence to support an important role of cortically located ASIC1a channel in pain hypersensitivity through promoting long-term synaptic potentiation in the ACC. Our results indicate a promising translational potential of targeting ASIC1a to treat chronic pain.
Subject(s)
Acid Sensing Ion Channels/biosynthesis , Gyrus Cinguli/metabolism , Isoenzymes/deficiency , Neuralgia/metabolism , Neuronal Plasticity/physiology , Pain Measurement/methods , Protein Kinase C/deficiency , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Acid Sensing Ion Channels/genetics , Animals , Cells, Cultured , Gyrus Cinguli/drug effects , Isoenzymes/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Microinjections/methods , Neuralgia/genetics , Neuralgia/prevention & control , Neuronal Plasticity/drug effects , Organ Culture Techniques , Pain Measurement/drug effects , Protein Kinase C/geneticsABSTRACT
Neuronal amyloid ß1-42 (Aß1-42) accumulation is considered an upstream event in Alzheimer's disease pathogenesis. Here we report the mechanism on synaptic activity-independent Aß1-42 uptake in vivo. When Aß1-42 uptake was compared in hippocampal slices after incubating with Aß1-42, In vitro Aß1-42 uptake was preferentially high in the dentate granule cell layer in the hippocampus. Because the rapid uptake of Aß1-42 with extracellular Zn2+ is essential for Aß1-42-induced cognitive decline in vivo, the uptake mechanism was tested in dentate granule cells in association with synaptic activity. In vivo rapid uptake of Aß1-42 was not modified in the dentate granule cell layer after co-injection of Aß1-42 and tetrodotoxin, a Na+ channel blocker, into the dentate gyrus. Both the rapid uptake of Aß1-42 and Zn2+ into the dentate granule cell layer was not modified after co-injection of CNQX, an AMPA receptor antagonist, which blocks extracellular Zn2+ influx, Both the rapid uptake of Aß1-42 and Zn2+ into the dentate granule cell layer was not also modified after either co-injection of chlorpromazine or genistein, an endocytic repressor. The present study suggests that Aß1-42 and Zn2+ are synaptic activity-independently co-taken up into dentate granule cells in the normal brain and the co-uptake is preferential in dentate granule cells in the hippocampus. We propose a hypothesis that Zn-Aß1-42 oligomers formed in the extracellular compartment are directly incorporated into neuronal plasma membranes and form Zn2+-permeable ion channels.
Subject(s)
Amyloid beta-Peptides/metabolism , Brain/metabolism , Dentate Gyrus/metabolism , Peptide Fragments/metabolism , Synapses/metabolism , Zinc/metabolism , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Amyloid beta-Peptides/pharmacokinetics , Animals , Biological Transport/drug effects , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Hippocampus/metabolism , Male , Microscopy, Confocal , Peptide Fragments/pharmacokinetics , Rats, Wistar , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacology , Tetrodotoxin/administration & dosage , Tetrodotoxin/pharmacology , Zinc/pharmacokineticsABSTRACT
Since the peripheral serotoninergic pathway is involved in the development of radiation-induced nausea and vomiting, referred to as radiation sickness, serotonin 5-HT3 receptor antagonists are used as a preventive measure, although patients still suffer from these symptoms. Glutamate is known as the excitatory neurotransmitter and is involved in various autonomic symptoms. We investigated the effect of radiation on glutamate release in rats, as measured by in vivo brain microdialysis, and the effects of glutamate receptor antagonists on radiation-induced pica, which can be used as a behavioral assessment of radiation sickness in rats. A microdialysis probe was inserted into the hypothalamus of rats that received 4 Gy total-body irradiation (TBI) with or without pretreatment of 5-HT3 receptor antagonist (granisetron, 0.1 mg/kg, i.p.), and dialysates were collected for 3 h after TBI and subjected to HPLC assay of glutamate. In addition, rats were intracerebroventricularly injected with NMDA receptor antagonist (MK-801: 3 µg/rat) or AMPA receptor antagonist (CNQX: 1 µg/rat) before TBI, and radiation-induced pica was determined. An increase in glutamate release was observed within 1 h postirradiation. The increased glutamate release was suppressed by granisetron. We also found that CNQX, but not MK-801, effectively inhibited radiation-induced pica. These results indicate that the hypothalamic glutamatergic system contributes to radiation-induced pica through the AMPA receptors.
Subject(s)
Glutamic Acid/metabolism , Hypothalamus/physiology , Pica/etiology , Radiation Exposure , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Chromatography, High Pressure Liquid , Dizocilpine Maleate/administration & dosage , Excitatory Amino Acid Antagonists/administration & dosage , Granisetron/administration & dosage , Hypothalamus/metabolism , Injections, Intraventricular , Male , Microdialysis , Rats , Rats, Wistar , Serotonin Antagonists/administration & dosage , Whole-Body IrradiationABSTRACT
To assess the possible function of glutamate in the interaction between the dorsomedial hypothalamic nucleus-perifornical area (DMH-PeF) and the A5 pontine region (A5), cardiovascular and respiratory changes were studied in response to electrical stimulation of the DMH-PeF (1 ms pulses, 30-50 miA given at 100 Hz for 5 s) before and after the microinjection of kynurenic acid (non-specific glutamate receptor antagonist; 50 nl, 5 nmol), MK-801 (NMDA receptor antagonist; 50 nl, 50 nmol), CNQX (non-NMDA receptor antagonist; 50 nl, 50 nmol) or MCPG (metabotropic glutamate receptor antagonist; 50 nl, 5 nmol) within the A5 region. DMH-PeF electrical stimulation elicited a pressor (p < 0.001) and tachycardic response (p < 0.001) which was accompanied by an inspiratory facilitation characterised by an increase in respiratory rate (p < 0.001) due to a decrease in expiratory time (p < 0.01). Kynurenic acid within the A5 region decreased the tachycardia (p < 0.001) and the intensity of the blood pressure response (p < 0.001) to DMH-PeF stimulation. After the microinjection of MK-801 and CNQX into the A5 region, the magnitude of the tachycardia and the pressor response were decreased (p < 0.05 and p < 0.01; p < 0.001 and p < 0.05, respectively). After MCPG microinjection into the A5 region, a decrease in the tachycardia (p < 0.001) with no changes in the pressor response was observed during DMH-PeF stimulation. The respiratory response elicited by DMH-PeF stimulation was not changed after the microinjection of kynurenic acid, MK-801, CNQX or MCPG within the A5 region. These results suggest that A5 region glutamate receptors play a role in the cardiovascular response elicited from the DMH-PeF. The possible mechanisms involved in these interactions are discussed
Subject(s)
Animals , Male , Rats , Cardiovascular Physiological Phenomena , Dorsomedial Hypothalamic Nucleus/physiology , Fornix, Brain/physiology , Receptors, Glutamate/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Blood Pressure , Dizocilpine Maleate/administration & dosage , Electric Stimulation , Glycine/administration & dosage , Glycine/antagonists & inhibitors , Kynurenic Acid/administration & dosage , Tachycardia/physiopathology , MicroinjectionsABSTRACT
To assess the possible function of glutamate in the interaction between the dorsomedial hypothalamic nucleus-perifornical area (DMH-PeF) and the A5 pontine region (A5), cardiovascular and respiratory changes were studied in response to electrical stimulation of the DMH-PeF (1 ms pulses, 30-50 µA given at 100 Hz for 5 s) before and after the microinjection of kynurenic acid (non-specific glutamate receptor antagonist; 50 nl, 5 nmol), MK-801 (NMDA receptor antagonist; 50 nl, 50 nmol), CNQX (non-NMDA receptor antagonist; 50 nl, 50 nmol) or MCPG (metabotropic glutamate receptor antagonist; 50 nl, 5 nmol) within the A5 region. DMH-PeF electrical stimulation elicited a pressor (p < 0.001) and tachycardic response (p < 0.001) which was accompanied by an inspiratory facilitation characterised by an increase in respiratory rate (p < 0.001) due to a decrease in expiratory time (p < 0.01). Kynurenic acid within the A5 region decreased the tachycardia (p < 0.001) and the intensity of the blood pressure response (p < 0.001) to DMH-PeF stimulation. After the microinjection of MK-801 and CNQX into the A5 region, the magnitude of the tachycardia and the pressor response were decreased (p < 0.05 and p < 0.01; p < 0.001 and p < 0.05, respectively). After MCPG microinjection into the A5 region, a decrease in the tachycardia (p < 0.001) with no changes in the pressor response was observed during DMH-PeF stimulation. The respiratory response elicited by DMH-PeF stimulation was not changed after the microinjection of kynurenic acid, MK-801, CNQX or MCPG within the A5 region. These results suggest that A5 region glutamate receptors play a role in the cardiovascular response elicited from the DMH-PeF. The possible mechanisms involved in these interactions are discussed.
Subject(s)
Cardiovascular Physiological Phenomena , Dorsomedial Hypothalamic Nucleus/physiology , Fornix, Brain/physiology , Receptors, Glutamate/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Blood Pressure , Dizocilpine Maleate/administration & dosage , Electric Stimulation , Excitatory Amino Acid Antagonists/administration & dosage , Glycine/administration & dosage , Glycine/analogs & derivatives , Heart Rate , Kynurenic Acid/administration & dosage , Male , Microinjections , Rats , Respiratory Rate , Tachycardia/physiopathologyABSTRACT
The present study was carried out to investigate whether glutamatergic receptor mechanisms modulate the release of noradrenaline (NA) in the region of the median preoptic nucleus (MnPO) using intracerebral microdialysis techniques in freely moving rats. Perfusion of N-methyl-d-asparatate (NMDA, 10 and 50µM) through the microdialysis probe significantly enhanced dialysate NA concentration in the region of the MnPO. Local perfusion of the NMDA antagonist dizocilpine (MK801, 10 and 50µM) did not change the basal release of NA in the MnPO area. MK801 (10µM) administered together with NMDA antagonized the stimulant effect of NMDA (50µM). Perfusion of the non-NMDA agonist quisqualic acid (QA, 10 and 50µM) or kainic acid (KA, 10 and 50µM) significantly increased the NA release in the MnPO area. Perfusion of the non-NMDA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 and 50µM) had no effect on the NA release. CNQX (10µM) administered together with either QA (50µM) or KA (50µM) in the MnPO area prevented the stimulant effect of the agonists on the NA release. Nonhypotensive hypovolemia following subcutaneous injections of polyethylene glycol (PEG, 30%, 5ml) significantly elevated the NA level in the MnPO area. The PEG-induced elevation in the NA release was attenuated by perfusion of either MK801 (10µM) or CNQX (10µM). The present results suggest that glutamatergic synaptic inputs may act to enhance the release of NA in the MnPO area through both NMDA and non-NMDA receptors, and imply that these glutamatergic receptor mechanisms may be involved in the noradrenergic reguratory system for the body fluid balance.
Subject(s)
Glutamic Acid/physiology , Norepinephrine/metabolism , Preoptic Area/metabolism , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Dizocilpine Maleate/administration & dosage , Excitatory Amino Acid Agonists/administration & dosage , Excitatory Amino Acid Antagonists/administration & dosage , Kainic Acid/administration & dosage , Male , Microdialysis , N-Methylaspartate/administration & dosage , Quisqualic Acid/administration & dosage , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/agonists , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolismABSTRACT
Protein tyrosine kinase (PTK) mediated the tyrosine phosphorylation modification of neuronal receptors and ion channels. Whether such modification resulted in changes of physiological functions was not sufficiently studied. In this study we examined whether the hypoxic respiratory response-which is the enhancement of breathing in hypoxic environment could be affected by the inhibition of PTK at brainstem ventral respiratory neuron column (VRC). Experiments were performed on urethane anesthetized adult rabbits. Phrenic nerve discharge was recorded as the central respiratory motor output. Hypoxic respiratory response was produced by ventilating the rabbit with 10% O2-balance 90% N2 for 5 minutes. The responses of phrenic nerve discharge to hypoxia were observed before and after microinjecting PTK inhibitor genistein, AMPA receptor antagonist CNQX, or inactive PTK inhibitor analogue daidzein at the region of ambiguus nucleus (NA) at levels 0-2 mm rostral to obex where the inspiratory subgroup of VRC were recorded. Results were as follows: 1. the hypoxic respiratory response was significantly attenuated after microinjection of genistein and/or CNQX, and no additive effect (i.e., further attenuation of hypoxic respiratory response) was observed when genistein and CNQX were microinjected one after another at the same injection site. Microinjection of daidzein had no effect on hypoxic respiratory response. 2. Fluorescent immunostaining showed that hypoxia significantly increased the number of phosphotyrosine immunopositive neurons in areas surrounding NA and most of these neurons were also immunopositive to glutamate AMPA receptor subunit GluR1. These results suggested that PTK played an important role in regulating the hypoxic respiratory response, possibly through the tyrosine phosphorylation modification of glutamate AMPA receptors on the respiratory neurons of ventral respiratory neuron column.
Subject(s)
Brain Stem/physiology , Hypoxia/metabolism , Neurons/metabolism , Protein-Tyrosine Kinases/metabolism , Respiration , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Brain Stem/drug effects , Female , Male , Microinjections , Neurons/drug effects , Phosphotyrosine/metabolism , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Rabbits , Receptors, AMPA/metabolism , Respiration/drug effectsABSTRACT
A microanalysis of hunger-driven and palatability-driven feeding was carried out after muscimol-mediated inactivation of two frontal regions in rats, the agranular/dysgranular insular cortex (AIC) and the ventromedial prefrontal cortex (vmPFC). Food and water intake, feeding microstructure, and general motor activity were measured under two motivational conditions: food-deprived rats given standard chow or ad libitum-fed rats given a palatable chocolate shake. Muscimol infusions into the AIC diminished intake, total feeding duration, and average feeding bout duration for the palatable-food condition only but failed to alter exploratory-like behavior (ambulation or rearing). In contrast, intra-vmPFC muscimol infusions did not alter the overall intake of chow or chocolate shake. However, these infusions markedly increased mean feeding bout duration for both food types and produced a modest but significant reduction of exploratory-like behavior. The lengthening of feeding-bout duration and reduction in rearing were mimicked by intra-vmPFC blockade of AMPA-type but not NMDA-type glutamate receptors. Neither water consumption nor the microstructure of water drinking was affected by inactivation of either site. These results indicate a regional heterogeneity in frontal control of feeding behavior. Neural processing in AIC supports palatability-driven feeding but is not necessary for intake of a standard food under a food-restriction condition, whereas ventromedial prefrontal cortex, and AMPA signaling therein, modulates the duration of individual feeding bouts regardless of motivational context. Results are discussed in the context of regionally heterogeneous frontal modulation of two distinct components of feeding behavior: reward valuation based upon taste perception (AIC) vs switching between ingestive and non-ingestive (eg, exploratory-like) behavioral repertoires (vmPFC).
Subject(s)
Cerebral Cortex/physiology , Feeding Behavior , Hunger , Prefrontal Cortex/physiology , Taste , gamma-Aminobutyric Acid/physiology , 2-Amino-5-phosphonovalerate/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Cerebral Cortex/drug effects , Drinking/drug effects , Eating/drug effects , Excitatory Amino Acid Antagonists/administration & dosage , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Feeding Behavior/drug effects , GABA-A Receptor Agonists/administration & dosage , Hunger/drug effects , Male , Muscimol/administration & dosage , Prefrontal Cortex/drug effects , Rats , Rats, Sprague-Dawley , Taste/drug effectsABSTRACT
Several studies have pointed to the amygdala as a main limbic station capable of regulating different stressful states such as anxiety and depression. In this work it was our intention to determine the role of the central amygdala nucleus (CeA) on the execution of either anxiolytic and/or anti-depressant behaviors in the hibernating hamster (Mesocricetus auratus) via infusion of CeA with the antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) specific for α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) plus the specific agonist for α4 GABAAR i.e. 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP). Treatment with CNQX appeared to mainly prompt anti-depressant effects as shown by the achievements of swimming feats during forced swim test while THIP prevalently accounted for evident bouts of climbing when exposed to the same test. Moreover, even in the presence of the concomitant administration of both of these compounds, hamsters continued to spend more time in swimming despite this significant behavioral effect resulted to be numerically reduced for hamsters treated with only the α4 GABAAR agonist. Conversely, when these animals were tested in elevated plus maze (EPM), THIP tended to mostly favor anxiolytic activities as exhibited by stressed animals spending more time entering and remaining in EPM open arms. It was interesting to note that behavioral changes induced by both drugs appeared to be also responsible for glutamate receptor (GluR) expression differences as indicated by CNQX favoring an evident up-regulation of GluR2-containing neurons whereas THIP induced an up-regulation, this time of GluR1-containing neurons. Overall, the anti-depressant role of CNQX seems to be mostly attributed to elevated GluR2 levels while an anxiolytic-like effect of THIP was correlated to high GluR1values thereby proposing distinct GluRs as useful therapeutic sites against degenerative diseases such as depression-like behaviors.
Subject(s)
Amygdala/physiopathology , Anxiety/physiopathology , Depression/physiopathology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Amygdala/drug effects , Animals , Anxiety/drug therapy , Anxiety/genetics , Behavior, Animal/drug effects , Behavior, Animal/physiology , Cricetinae , Depression/drug therapy , Depression/genetics , Excitatory Amino Acid Antagonists/administration & dosage , GABA-A Receptor Agonists/administration & dosage , Isoxazoles/administration & dosage , Male , Mesocricetus , Microinjections , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, AMPA/drug effects , Receptors, AMPA/genetics , Receptors, AMPA/physiology , Stress, PhysiologicalABSTRACT
AMPAR (α-amino-3-hydroxy-5-methylisoxazole-4-propionate glutamate receptor) stimulation in the nucleus accumbens (NAc) is critical in cocaine seeking. Here, we investigate the functional interaction between D1 dopamine receptors (D1DR) and AMPARs in the NAc, and explore how A1 adenosine receptor (A1AR) stimulation may reduce dopamine-induced facilitation of AMPARs and cocaine seeking. All animals were trained to self-administer cocaine and were tested for reinstatement of cocaine seeking following extinction procedures. The role of AMPARs in both AMPA- and D1DR-induced cocaine seeking was assessed using viral-mediated gene transfer to bi-directionally modulate AMPAR activity in the NAc core. The ability of pharmacological AMPAR blockade to modulate D1DR-induced cocaine seeking also was tested. Immunoblotting was used to determine whether stimulating D1DR altered synaptic AMPA GluA1 phosphorylation (pGluA1). Finally, the ability of an A1AR agonist to modulate D1DR-induced cocaine seeking and synaptic GluA1 receptor subunit phosphorylation was explored. Decreasing AMPAR function inhibited both AMPA- and D1DR-induced cocaine seeking. D1DR stimulation increased AMPA pGluA1(S845). Administration of the A1AR agonist alone decreased synaptic GluA1 expression, whereas coadministration of the A1AR agonist inhibited both cocaine- and D1DR-induced cocaine seeking and reversed D1DR-induced AMPA pGluA1(S845). These findings suggest that D1DR stimulation facilitates AMPAR function to initiate cocaine seeking in D1DR-containing direct pathway NAc neurons. A1AR stimulation inhibits both the facilitation of AMPAR function and subsequent cocaine seeking, suggesting that reducing AMPA glutamate neurotransmission in direct pathway neurons may restore inhibitory control and reduce cocaine relapse.
Subject(s)
Cocaine/pharmacology , Drug-Seeking Behavior/drug effects , Nucleus Accumbens/metabolism , Receptor, Adenosine A1/metabolism , Receptors, AMPA/metabolism , Receptors, Dopamine D1/metabolism , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Adenosine/administration & dosage , Adenosine/analogs & derivatives , Adenosine/pharmacology , Animals , Benzazepines/administration & dosage , Benzazepines/pharmacology , Cocaine/administration & dosage , Dopamine Agonists/pharmacology , Drug Interactions , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Extinction, Psychological , Gene Transfer Techniques , Male , Microinjections , Nucleus Accumbens/drug effects , Phosphorylation/drug effects , Purinergic P1 Receptor Agonists/pharmacology , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Rats , Receptors, AMPA/genetics , Self Administration , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacologyABSTRACT
RATIONALE: Glutamate and orexin/hypocretin systems are involved in Pavlovian cue-triggered drug seeking. OBJECTIVES: Here, we asked whether orexin and glutamate interact within ventral tegmental area (VTA) to promote reinstatement of extinguished cocaine seeking in a rat self-administration paradigm. METHODS/RESULTS: We first found that bilateral VTA microinjections of the orexin 1 receptor (OX1R) antagonist SB-334867 (SB) or a cocktail of the AMPA and NMDA glutamate receptor antagonists CNQX/AP-5 reduced reinstatement of cocaine seeking elicited by cues. In contrast, neither of these microinjections nor systemic SB reduced cocaine-primed reinstatement. Additionally, unilateral VTA OX1R blockade combined with contralateral VTA glutamate blockade attenuated cue-induced reinstatement, indicating that VTA orexin and glutamate are simultaneously necessary for cue-induced reinstatement. We further probed the receptor specificity of glutamate actions in VTA, finding that CNQX, but not AP-5, dose-dependently attenuated cue-induced reinstatement, indicating that AMPA but not NMDA receptor transmission is required for this type of cocaine seeking. Given the necessary roles of both OX1 and AMPA receptors in VTA for cue-induced cocaine seeking, we hypothesized that these signaling pathways interact during this behavior. We found that PEPA, a positive allosteric modulator of AMPA receptors, completely reversed the SB-induced attenuation of reinstatement behavior. Intra-VTA PEPA alone did not alter cue-induced reinstatement, indicating that potentiating AMPA activity with this drug specifically compensates for OX1R blockade, rather than simply inducing or enhancing reinstatement itself. CONCLUSIONS: These findings show that cue-induced, but not cocaine-primed, reinstatement of cocaine seeking is dependent upon orexin and AMPA receptor interactions in VTA.
Subject(s)
Cocaine/administration & dosage , Glutamic Acid/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Neuropeptides/metabolism , Ventral Tegmental Area/metabolism , 2-Amino-5-phosphonovalerate/administration & dosage , 2-Amino-5-phosphonovalerate/pharmacology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Benzoxazoles/pharmacology , Cues , Dose-Response Relationship, Drug , Drug-Seeking Behavior , Male , Naphthyridines , Orexin Receptors , Orexins , Rats , Rats, Sprague-Dawley , Receptors, AMPA/antagonists & inhibitors , Receptors, G-Protein-Coupled/drug effects , Receptors, G-Protein-Coupled/metabolism , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, Neuropeptide/drug effects , Receptors, Neuropeptide/metabolism , Self Administration , Signal Transduction , Urea/analogs & derivatives , Urea/pharmacologyABSTRACT
BACKGROUND: The ventral tegmental area (VTA) is a pivotal relay site within the reinforcement circuit that has been shown to play a role in ethanol (EtOH)-motivated behaviors. The primary dopamine projections within this system originate in the VTA and innervate several areas including the nucleus accumbens (NAc) and prefrontal cortex (PFC), and the PFC has afferent glutamate projections to the VTA and the NAc. The following studies utilized 2 different operant paradigms, one focusing on reinforcer-seeking and the other on reinforcer drinking (both with an EtOH and a sucrose reinforcer solution), to elucidate regulation of these behaviors by the posterior VTA, and the specific roles of dopamine and glutamate in this region. METHODS: The present experiments assessed the effects of microinjections of the glutamate (AMPA/kainate) antagonist CNQX and the dopamine D1-like antagonist SCH23390 in the posterior VTA, as well as transient chemical inactivation of this region using tetrodotoxin (TTX). In 4 separate experiments (2 dopamine, 2 glutamate, both with TTX), male Long Evans rats were trained to complete a single response requirement that resulted in access to 10% EtOH or 2% sucrose for a 20-minute drinking period. RESULTS: Prior to microinjections, EtOH-reinforced subjects were consuming approximately 0.45 to 0.65 g/kg EtOH and making approximately 50 responses during intermittent nonreinforced artificial cerebrospinal fluid sessions (Sucrose groups had similar baseline response levels). Overall, TTX inactivation of the VTA consistently decreased reinforcer-seeking but not intake in all experiments. CNQX also dose-dependently decreased EtOH-seeking, with no significant effect on sucrose-seeking or reinforcer intake. SCH23390 had no significant effects on reinforcer-seeking, and very moderately decreased intake of both EtOH and sucrose. CONCLUSIONS: Inactivation of the posterior VTA implicated this region in reinforcer-seeking as opposed to reinforcer intake. Overall, the present findings provide support for the importance of posterior VTA glutamate activity specifically in EtOH-seeking behavior in animals consuming pharmacologically relevant amounts of EtOH.
Subject(s)
Alcohol Drinking/metabolism , Behavior, Addictive/metabolism , Dopamine/physiology , Glutamic Acid/physiology , Reinforcement, Psychology , Ventral Tegmental Area/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Ethanol/administration & dosage , Excitatory Amino Acid Antagonists/administration & dosage , Male , Microinjections/methods , Rats , Rats, Long-Evans , Ventral Tegmental Area/drug effectsABSTRACT
RATIONALE: Glutamatergic projection neurons in the medial prefrontal cortex (mPFC) are hyperexcitable in cocaine-sensitized animals, resulting in increased excitatory output to addiction-associated regions such as the ventral tegmental area (VTA) and nucleus accumbens. Evidence suggests that Group I metabotropic glutamate receptor 5 (mGluR5) is necessary for cocaine sensitization, and stimulation of this receptor in the mPFC potentially alters cell excitability directly through glutamate release or indirectly through downstream signaling cascades. OBJECTIVES AND METHODS: Experiments in this report examined the role of mPFC mGluR5 in behavioral sensitization to cocaine. Group I mGluR agonist dihydroxyphenylglycine (DHPG) (15 nmol/side), mGluR5 antagonist 3((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP) (15 nmol/side), mGluR1 antagonist YM298198 (15 nmol/side), AMPA receptor antagonist CNQX (1 nmol/side), and/or saline were administered through cannulae implanted 1 mm above the mPFC and/or VTA in male rats. Cocaine (15 mg/kg, i.p.) was systemically administered for four consecutive days to induce sensitization and/or once on test day immediately preceding locomotor monitoring. RESULTS: Intra-mPFC DHPG induced an mGluR5-mediated cross-sensitization to cocaine preventable through the prior administration of an AMPA receptor antagonist in the VTA. Furthermore, mGluR5 blockade in the mPFC failed to prevent the initiation of sensitization. However, intra-mPFC injections of the mGluR5 antagonist MTEP prevented the expression of cocaine sensitization at 21, but not 7, days following daily cocaine injections suggesting a possible role for mPFC mGluR5 in the persistence of the cocaine-sensitized state. CONCLUSIONS: These data suggest that stimulation of mGluR5s in the mPFC is sufficient to induce cocaine sensitization and is necessary for the expression of this sensitized response.
Subject(s)
Central Nervous System Sensitization/physiology , Cocaine/pharmacology , Prefrontal Cortex/physiology , Receptors, Metabotropic Glutamate/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Benzimidazoles/administration & dosage , Benzimidazoles/pharmacology , Central Nervous System Sensitization/drug effects , Cocaine/agonists , Cocaine/antagonists & inhibitors , Drug Interactions , Excitatory Amino Acid Agonists/administration & dosage , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Glycine/administration & dosage , Glycine/analogs & derivatives , Glycine/pharmacology , Male , Microinjections , Motor Activity/drug effects , Motor Activity/physiology , Prefrontal Cortex/drug effects , Pyridines/administration & dosage , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5 , Receptors, AMPA/antagonists & inhibitors , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Resorcinols/administration & dosage , Resorcinols/pharmacology , Thiazoles/administration & dosage , Thiazoles/pharmacology , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/physiologyABSTRACT
We demonstrate targeted perturbation of neuronal activity with controlled release of neurochemicals from conducting polymer-coated microelectrodes. Polymer coating and chemical incorporation are achieved through individually addressable electrodeposition, a process that does not compromise the recording capabilities of the electrodes. Release is realized by the application of brief voltage pulses that electrochemically reduce the polymer and dissociate incorporated neurochemicals; whereby they can diffuse away and achieve locally effective concentrations. Inhibition of evoked synaptic currents in neurons within 200 µm of a 6-cyano-7-nitroquinoxaline-2,3-dione releasing electrode lasts for several seconds. Spiking activity of neurons in local circuits recorded extracellularly near the releasing electrode is silenced for a similar duration following release. This methodology is compatible with many neuromodulatory chemicals and various recording electrodes, including in vitro and implantable neural electrode arrays, thus providing an inexpensive and accessible technique capable of achieving sophisticated patterned chemical modulation of neuronal circuits.
Subject(s)
Microelectrodes , Neurons/drug effects , Neurons/physiology , Polymers , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Cells, Cultured , Contrast Media , Data Interpretation, Statistical , Delayed-Action Preparations , Diffusion , Electric Impedance , Electrochemistry , Electrodes, Implanted , Electrophysiological Phenomena , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Fluorescein/administration & dosage , Fluorescein/chemistry , Nerve Net/cytology , Nerve Net/physiology , Patch-Clamp Techniques , Rats , Synapses/drug effects , Synaptic Potentials/drug effectsABSTRACT
The electroretinogram is a widely used objective measure of visual function. The best characterised feature of the full-field dark-adapted flash ERG, is the earliest corneal negativity, the a-wave, which primarily reflects photoreceptoral responses. However, recent studies in humans and primates show that there are post-receptoral contributions to the a-wave. It is not clear if such contributions exist in the rat a-wave. We consider this issue in the rat a-wave, using intravitreal application of pharmacological agents that isolate post-receptoral ON-pathways and OFF-pathways. In anaesthetised adult long Evans rats, we show that the ON-pathway (2-amino-4-phosphonobutyric acid, APB sensitive) makes negligible contribution to the a-wave. In contrast, CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) or PDA (cis-piperidine-2,3-dicarboxylic acid) sensitive mechanisms modify the a-wave in two ways. First, for bright luminous energies, OFF-pathway inhibition (CNQX or PDA) results in a 22% reduction to the early phase of the leading edge of the a-wave up to 14 ms. Second, OFF-pathway inhibition removed a corneal negativity that resides between the a-wave trough and the b-wave onset.
Subject(s)
Electroretinography/methods , Night Vision/physiology , Retinal Rod Photoreceptor Cells/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Aminobutyrates/administration & dosage , Animals , Dark Adaptation/physiology , Intravitreal Injections , Night Vision/drug effects , Pipecolic Acids/administration & dosage , Rats , Rats, Long-Evans , Retinal Rod Photoreceptor Cells/drug effectsABSTRACT
The present study was conducted to evaluate the influence of the glutamatergic receptors α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic glutamate 5 (mGlu5) receptors on sensitization to the rewarding effects of morphine. The effects of pre-treatment with saline or 20mg/kg morphine plus the AMPA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (5 or 10mg/kg) or the metabotropic Glu5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) (5 or 10mg/kg) on the place conditioning induced by a low dose of morphine (2mg/kg) were assessed. The 2mg/kg dose of morphine was ineffective in animals pre-treated with saline but induced a clear conditioned place preference (CPP) in mice pre-treated with morphine alone and morphine plus any of the MPEP doses or the lowest dose of CNQX. Conversely, animals pre-treated with morphine plus 10mg/kg of CNQX did not acquire CPP. Our results suggest that AMPA glutamate receptors are involved in the development of sensitization to the conditioned rewarding effects of morphine.
Subject(s)
Morphine/administration & dosage , Receptors, AMPA/metabolism , Receptors, Metabotropic Glutamate/metabolism , Reward , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Male , Mice , Pyridines/administration & dosage , Pyridines/pharmacology , Receptor, Metabotropic Glutamate 5 , Receptors, AMPA/antagonists & inhibitors , Receptors, Metabotropic Glutamate/antagonists & inhibitorsABSTRACT
Treatment to block the pathophysiological processes triggered by acute spinal injury remains unsatisfactory as the underlying mechanisms are incompletely understood. Using as a model the in vitro spinal cord of the neonatal rat, we investigated the feasibility of neuroprotection of lumbar locomotor networks by the glutamate antagonists 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX) and aminophosphonovalerate (APV) against acute lesions induced by either a toxic solution (pathological medium (PM) to mimic the spinal injury hypoxic-dysmetabolic perturbation) or excitotoxicity with kainate. The study outcome was presence of fictive locomotion 24 h after the insult and its correlation with network histology. Inhibition of fictive locomotion by PM was contrasted by simultaneous and even delayed (1 h later) co-application of CNQX and APV with increased survival of ventral horn premotoneurons and lateral column white matter. Neither CNQX nor APV alone provided neuroprotection. Kainate-mediated excitotoxicity always led to loss of fictive locomotion and extensive neuronal damage. CNQX and APV co-applied with kainate protected one-third of preparations with improved motoneuron and dorsal horn neuronal counts, although they failed with delayed application. Our data suggest that locomotor network neuroprotection was possible when introduced very early during the pathological process of spinal injury, but also showed how the borderline between presence or loss of locomotor activity was a very narrow one that depended on the survival of a certain number of neurons or white matter elements. The present report provides a model not only for preclinical testing of novel neuroprotective agents, but also for estimating the minimal network membership compatible with functional locomotor output.
Subject(s)
2-Amino-5-phosphonovalerate/pharmacology , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Locomotion/drug effects , Neuroprotective Agents/pharmacology , Spinal Cord Injuries/drug therapy , 2-Amino-5-phosphonovalerate/administration & dosage , 6-Cyano-7-nitroquinoxaline-2,3-dione/administration & dosage , Animals , Animals, Newborn , Cell Survival/drug effects , Disease Models, Animal , Drug Therapy, Combination , Efferent Pathways/drug effects , Efferent Pathways/physiopathology , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , In Vitro Techniques , Kainic Acid , Locomotion/physiology , Motor Neurons/drug effects , Motor Neurons/physiology , Nerve Fibers, Myelinated/drug effects , Nerve Fibers, Myelinated/physiology , Neurons/drug effects , Neurons/physiology , Neuroprotective Agents/administration & dosage , Posterior Horn Cells/drug effects , Posterior Horn Cells/physiology , Rats , Rats, Wistar , Spinal Cord Injuries/chemically induced , Spinal Cord Injuries/physiopathology , Time FactorsABSTRACT
Upon entering the neocortex, neural signals are required to select which neocortical circuits to propagate through. The present study focused attention on use-dependent selection of signal-traveling routes. Rat brain slices including primary visual cortex (Oc1) and the medial part of the secondary visual cortex (Oc2M) were prepared. Electrical stimulation was delivered to white matter in Oc1 and spatiotemporal aspects of traveling signals were observed using optical recording methods under caffeine application. With an interstimulus interval (ISI) of 4-8s, signals traveled horizontally along deep layers from Oc1 to Oc2M, climbed within Oc2M, then returned along layer II/III from Oc2M to Oc1. Conversely, with an ISI of 40-64s, signals climbed within Oc1 and traveled horizontally along layer II/III from Oc1 to Oc2M in parallel with signals traveling along deep layers. Pharmacological experiments with antagonists for ionotropic glutamate receptors revealed that signal-traveling routes under higher-frequency stimulation were N-methyl-d-aspartate (NMDA) receptor activity-dependent, while those at the lower-frequency were non-NMDA receptor activity-dependent. These results suggest that neural circuits between Oc1 and Oc2M possess an input frequency-dependent gating system, in which signal-traveling routes might be affected by the relative balance of receptor activities between NMDA and non-NMDA receptors.